Vile R - Search Results

1

Oncolytic virus-derived type I interferon restricts CAR T cell therapy.

Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, Archer G, Sampson J, Pulido J, Perez LS, Vile R. Evgin L, et al. Among authors: vile r. Nat Commun. 2020 Jun 24;11(1):3187. doi: 10.1038/s41467-020-17011-z. Nat Commun. 2020. PMID: 32581235 Free PMC article.

2

Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.

Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, Linardakis E, Riddle D, Dietz A, Lohse CM, Strome S, Peterson T, Simari R, Vile RG. Bateman AR, et al. Among authors: vile rg. Cancer Res. 2002 Nov 15;62(22):6566-78. Cancer Res. 2002. PMID: 12438252

3

A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization.

Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp RD, Suzuki K, Alemany R, Harrington K, Vile RG. Ahmed A, et al. Among authors: vile rg. Nat Biotechnol. 2003 Jul;21(7):771-7. doi: 10.1038/nbt835. Epub 2003 Jun 8. Nat Biotechnol. 2003. PMID: 12794639

4

Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.

Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R. Crittenden M, et al. Among authors: vile r. Cancer Res. 2003 Jun 15;63(12):3173-80. Cancer Res. 2003. PMID: 12810645

5

Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.

Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S, Harrington K, Bateman A, Vile R. Ahmed A, et al. Among authors: vile r. Gene Ther. 2003 Sep;10(19):1663-71. doi: 10.1038/sj.gt.3302064. Gene Ther. 2003. PMID: 12923565

6

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.

Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R. Phan V, et al. Among authors: vile r. Nat Med. 2003 Sep;9(9):1215-9. doi: 10.1038/nm923. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925849

7

Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity.

Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Crittenden M, et al. Cancer Res. 2003 Sep 1;63(17):5505-12. Cancer Res. 2003. PMID: 14500387

8

A simple method to cure established tumors by inflammatory killing of normal cells.

Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. Daniels GA, et al. Nat Biotechnol. 2004 Sep;22(9):1125-32. doi: 10.1038/nbt1007. Epub 2004 Aug 1. Nat Biotechnol. 2004. PMID: 15300260 Free article.

9

Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG. Sanchez-Perez L, et al. Cancer Res. 2005 Mar 1;65(5):2009-17. doi: 10.1158/0008-5472.CAN-04-3216. Cancer Res. 2005. PMID: 15753401

10

Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy.

Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovic D, Vile R. Gough M, et al. Among authors: vile r. J Immunol. 2005 May 1;174(9):5766-73. doi: 10.4049/jimmunol.174.9.5766. J Immunol. 2005. PMID: 15843579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

307 results

Search Page